Polymorphisms in ERCC1 and ERCC2/XPD and Survival in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin Based Chemotherapy.
- Author:
Jeong Seon RYU
1
;
Yun Chul HONG
;
Hye Seung HAN
;
Jong Eun LEE
;
Sook KIM
;
Young Mee PARK
;
Young Chul KIM
;
Jae Hwa CHO
;
Hong Lyeol LEE
;
Tae Sook HWANG
Author Information
1. Department of Internal Medicine, College of Medicine, Inha University, Incheon, Korea. jsryu@inha.ac.kr
- Publication Type:Original Article
- Keywords:
Non-small-cell lung cancer;
ERCC1;
ERCC2/XPD;
Nucleotide excision repair
- MeSH:
Biomarkers;
Body Weight;
Cisplatin*;
Complement System Proteins;
DNA Repair;
Drug Therapy*;
Genotype;
Humans;
Lung Neoplasms*;
Lung*;
Paclitaxel;
Prognosis;
Survival Rate
- From:Journal of Lung Cancer
2003;2(1):44-53
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The expressions of low levels of ERCC1 (excision repair crosscomplementation group 1) and ERCC2/XPD (excision repair cross- complementation group 2) have been studied in order to find a potential marker for predicting the prognosis or treatment response in cancer patients. However, polymorphisms in these genes have been rarely evaluated in terms of predicting the survival of cancer patients. MATERIALS AND METHODS: We investigated whether these polymorphisms had an effect on the response to chemotherapy and on the survival in 109 patients, with non-small-cell lung cancer, treated with cisplatin plus gemcitabine, paclitaxel or docetaxel. The polymorphisms of ERCC1 Asn118Asn (C->T), ERCC2 Lys751Gln and Asp312Asn were evaluated using a SNaPshot kit. RESULTS: The treatment responses showed no statistically significant differences according to the polymorphisms of ERCC1 Asn118Asn, ERCC2 Lys751Gln or Asp312Asn. The median survival time was 376 days (95% CI, 291~488). The overall survival rate showed no significant difference according to age, sex, chemotherapy regimen, clinical stage or sequential radiation therapy. The polymorphisms of ERCC2 Lys751Gln and Asp312Asn did not affect the survival of the patients (p=0.4711 and 0.4542, respectively). The polymorphism of ERCC1 Asn118Asn, chemotherapy response, performance status and body weight loss had effect on the overall survival of the patients (p=0.0001, 0.0001, 0.0176 and 0.0082 respectively). As for survival rate, according to the polymorphism in ERCC1 Asn118Asn, the median survival time in those patients showing the wild genotype (C/C) was 480 days (95% CI, 333~544), which was statistically significant compared with the 281 days for the patients with the variant genotype (T/T, C/T) (hazard ratio 3.497) (95% CI, 214~376). CONCLUSION: It is suggested that the presence of the wild genotype in ERCC1 Asn118Asn, in non-small-cell lung cancer patients treated with cisplatin based chemotherapy, was a surrogate marker for predicting a better survival.
